ArticleThe Lancet. Infectious diseases2026

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

Lindsey R Baden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.